Clinical Features and Outcome of Primary Amyloidosis in Korea Kihyun Kim, Seok Jin Kim, Hyun Jung Jun,Yeung-Chul Mun, Chul Soo Kim, Jong-Ho Won, Soo-Mee.

Slides:



Advertisements
Similar presentations
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Advertisements

Randomized phase 3 study of rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in newly diagnosed.
PLASMA CELL DYSCRASIAS Monoclonal gammopathy of uncertain significance (MGUS)  Idiopathic  Associated with other diseases (autoimmune, infectious, non-heme.
CHEMOTHERAPY FOR PRIMARY HEPATIC MALIGNANCIES Maria Poulou, Eleni Makropoulou, Evangelos Repassos, Emanuel Xydakis, Maria Papadakou, Gerasimos Panagos.
Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June , McCormick.
Objectives To introduce the terminology used in describing the plasma cells neoplasm. To explain the physiology of the normal cells & the pathological.
Total Lesion Glycolysis by 18 F-FDG PET/CT a Reliable Predictor of Prognosis in Soft Tissue Sarcoma Ilkyu Han Musculoskeletal Tumor Center, Seoul National.
This lecture was conducted during the Nephrology Unit Grand Ground by a Sub- intern under Nephrology Division, Department of Medicine in King Saud University.
Experience and Outcomes with Hypofractionated Concurrent Chemoradiation for Stage III NSCLC at NCCC Gregory Webb Medical Student.
Incidence and clinical significance of intrapulmonary shunt in biliary atresia Eun Young Chang, Young Ju Hong, Jung-Tak Oh, Seok Joo Han 65 th Annual Congress.
QUIZ OF THE WEEK By .. Shada AlGhamdi.
Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.
S L I D E 0 Invasive Mediastinal Staging Does Not Improve Outcomes Over PET Alone in Early-Stage NSCLC Treated with SBRT Christopher D. Corso MD PhD, Shane.
What would you recommend as first line therapy for a 68 y/o woman with advanced pancreatic cancer and limited metastatic disease with ECOG-1? Gemcitabine.
MANAGEMENT OF MANTLE CELL LYMPHOMA IN TUNISIA R BEN LAKHAL, L KAMMOUN, K ZAHRA, S KEFI Sousse 25 MAY 2012.
Ki Cheol Chang, MD 1, 2, Mee Kum Kim, MD 1, 2, Won Ryang Wee, MD 1,2, Jin Hak Lee, MD 2,3, Beom Seok Jeon, MD 4 Department of Ophthalmology, Seoul National.
Plasma cell disorders Dr. hassanali vahedian ardakani Medical oncologist hematologist 2013.
Results of Docetaxel Plus Oxaliplatin (DOCOX) +/- Cetuximab in Patients with Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma: Results.
Conclusion IS SECOND LINE SYSTEMIC CHEMOTHERAPY BENEFICIAL IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)? : A MULTICENTER DATA EVALUATION (ANATOLIAN.
Current Status of Acute Myeloid Leukemia in China Jianxiang Wang Institute of Hematology Hospital of Blood Disease Chinese Academy of Medical Sciences.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria MULTIPLE MYELOMA.
A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.
Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney Sophina Hissaund FY2.
Cmab might have therapeutic benefit in Japanese patients with KRAS p.G13D mutant colorectal cancer. Limitations of this study are its retrospective design.
ECCO ESMO 2011 GI Cancer Updates TAS102 and BSC vs. Placebo and BSC Reviewer: Dr. Scott Berry Date posted: October 2011.
Gray Zone Lymphoma (GZL) with Features Intermediate between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective.
Table 1. Characteristics of patients and the results of the log-rank test of prognostic factors Median (range) No. of patients No. of CRPC Median progression.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Mun Hyuk Seong,1 Ho Kil,1 Young Seok Kim,2 Si Hyun Bae,3 Youn Jae Lee,4 Han Chu Lee,5 Byung Hak Kang,6 and Sook-Hyang Jeong1* Clinical and Epidemiological.
CLINICAL OUTCOME OF 251 PATIENTS WITH EXTRAHEPATIC METASTASIS AT INITIAL DIAGNOSIS OF HEPATOCELLULAR CARCINOMA: DOES TRANSARTERIAL CHEMOEMBOLIZATION IMPROVE.
1 Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma:a retrospective study Hilmi Ege, Morie A.Gertz,
Biochemical and genetic evaluation in amyloidosis
A European Collaborative Study of 230 Patients to Assess the Role of Cyclophosphamide, Bortezomib and Dexamethasone in Upfront Treatment of Patients with.
Is the early cyclosporine A level predictive of the outcome of immunosuppressive therapy in severe aplastic anemia? Eur J Haematol Feb. R2 이 홍 주.
Evaluating the Clinical Outcomes of Sixty-Three Patients Treated with Gamma Knife as Salvage Therapy for Glioblastoma Multiforme Erik W Larson, Halloran.
Ki Tae Suk, MD 1, Dong Joon Kim, MD 1, Chang Hoon Kim, BS 2, Seung Ha Park, MD 3, Jai Hoon Yoon, MD 1, Yeon Soo Kim, MD 1, Gwang Ho Baik, MD 1, Jin Bong.
Morie Gertz Chair Dept. of Medicine
Accelerated radical radiotherapy for Non Small Cell Lung Cancer: Single centre audit outcome of two fractionations in the treatment of the elderly patients.
International Neurourology Journal 2010;14:
Perioperative Complications after Neoadjuvant Chemoradiation for Locally-Advanced Esophageal Cancer: A Comparison of Platinum/5-FU and Carboplatin/Paclitaxel.
Early Surgery versus Conventional Treatment for Infective Endocarditis
Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.
Presented By Michael Lee at 2016 ASCO Annual Meeting
Cirrhotic Ascites Patient Population Survey in Korea
International Neurourology Journal 2013;17:24-29
ASCT for AL Seok Jin Kim
Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
Changes in Serologic Markers of Hepatitis B Following Autologous Hematopoietic Stem Cell Transplantation  Ji Eun Uhm, Kihyun Kim, Tae Kyu Lim, Byeong-Bae.
The 44th Congress of the Korean Association of HBP Surgery
Improved survival outcomes after resection of ductal adenocarcinoma in the body and tail of the pancreas: A single center 10 years’ experience Seong.
Fenaux P et al. Lancet Oncol 2009;10(3):
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic.
Who Are Less Likely to Receive Subsequent Chemotherapy Beyond First-Line Therapy for Advanced Non-small Cell Lung Cancer?: Implications for Selection.
A subgroup analysis of a large multicenter study
Infused CD34+ cell dose predicts long-term survival in acute myelogenous leukemia patients who received allogeneic bone marrow transplantation from matched.
Complete Remission Status before Autologous Stem Cell Transplantation Is an Important Prognostic Factor in Patients with Multiple Myeloma Undergoing Upfront.
International Neurourology Journal 2015;19:
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p  Sandy W. Wong, Ute Hegenbart, Giovanni Palladini,
Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia  Hawk Kim, Kyoo-Hyung Lee, Sung-Soo Yoon, Sang.
Prognostic Factors and Clinical Outcomes of High-Dose Chemotherapy followed by Autologous Stem Cell Transplantation in Patients with Peripheral T Cell.
Metal versus plastic stents for drainage of malignant biliary obstruction before primary surgical resection  Tae Jun Song, MD, PhD, Jae Hoon Lee, MD,
High-Dose Etoposide Plus Granulocyte Colony-Stimulating Factor as an Effective Chemomobilization Regimen for Autologous Stem Cell Transplantation in Patients.
Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma 
Gastrointestinal Endoscopy
Clinical Lymphoma, Myeloma and Leukemia
The SUV on 18F-FDG-PET/CT imaging as an independent predictor for overall survival and disease free survival after hepatectomy of Hepatocellular carcinoma(
Prognostic effect of complete pathologic response following TACE on HCC patients undergoing liver resection or transplantation Prognostic effect of complete.
Surgical resection of metachronous liver metastases
Introduction and Objectives
Presentation transcript:

Clinical Features and Outcome of Primary Amyloidosis in Korea Kihyun Kim, Seok Jin Kim, Hyun Jung Jun,Yeung-Chul Mun, Chul Soo Kim, Jong-Ho Won, Soo-Mee Bang, Jae Hoon Lee

Primary Amyloidosis a monoclonal plasma cell disorder the accumulation of monoclonal light chain fragments that have undergone a conformational transformation and deposit as amyloid fibrils in different tissues. Organ dysfunction such as heart, kidney, liver, peripheral nervous system are common clinical features Primary Amyloidosis in Korea –No data about epidemiology or clinical characteristics or treatment outcome are available.

Objectives and Methods To describe clinical features and outcome of primary amyloidosis in Korea Diagosed from 1995 to 2010 Multicenter : 6 centers Retrospective chart review

Patient characteristics

Treatment

Overall Survival N=88 Median 21.6 months

P=0.003 Median OS 24.8 vs vs. 3.3 months Age 65 P=0.67 Year of diagnosis

Hematologic Response P=0.001 Median OS NR vs months Organ Response P=0.009 Median OS NR vs months Cardiac Involvement P<0.001 Median OS 38.2 vs. 8.4 months SC Transplantation P=0.03 Median OS NR vs months

Renal Involvement P=0.268 Hepatic Involvement P=0.003 Median OS 23.9 vs. 3.3 months No of Organ Involvement P=0.002 Median OS 43.8 vs vs. 9.2 months BM Plasma cell 30% P=0.049 Median OS 22.6 vs. 8.5 months

iFLC high vs. low P=0.139 NYHA FC 1 vs 2 or more P=0.003 Median OS 29.0 vs. 4.5 months NT-proBNP normal vs. abnormal P=0.023 ECOG PS 0, 1 vs 2 or more P<0.001 Median OS 24.8 vs. 3.3 months

Prognostic Factors

Summary & Conclusion We could described clinical features and outcome of Korean amyloidosis patients. The most common treatment regimen were akylating agent plus dexamethasone or predinisolone. Hematologic response, organ response, cardiac involvement, hepatic involvement, number of organ involvement, extent of BM plamacytosis, stem cell transplantation, NYHA functional grade, ECOG performance status, NT-proBNP were significant for overall survival in univariate analysis, and Hematologic response and ECOG performance status were significant prognostic in multivariate analysis.

Acknowledgement Kihyun Kim, Seok Jin Kim, Hyun Jung Jun –Samsung Medical Center, Sungkyunkwan University School of Medicine Yeung-Chul Mun –Ewha Womans University School of Medicine Chul Soo Kim –Comprehensive Cancer Center, Inha University Hospital Jong-Ho Won –Soonchunhyang University Hospital Soo-Mee Bang –Seoul National University Bundang Hospital Jae Hoon Lee –Gachon University Gil Hospital